42C IX Biopharma
- 0.038
- -0.001-2.56%
IX Biopharma News
IX Biopharma Advances in Drug Development
Singaporean Shares End Marginally Higher; Biopharma's Shares Climb 2% on Introduction of New Sublingual Wafer
Singapore Strait Times Index rose on Tuesday at the close, tracking overnight gains in the global markets after global equities ended mixed overnight. During the day, the benchmark index ranged betwee
IX Biopharma Targets Diabetes With New Wafer
Singapore Stocks Linger in Red; IX Biopharma's Shares Soar 12% Following Unveiling of Novel Drug Delivery System
Singapore Strait Times Index opened marginally higher on Tuesday but slipped back into the negative territory at the close, following overnight losses in global markets. During the day, the benchmark
IX Biopharma Unveils Novel Drug Delivery System; Shares Surge 12%
iX Biopharma (SGX:42C) unveiled a specialized drug delivery system, the NAD wafers at the Center for Healthy Longevity Conference, according to a Monday filing. Through this non-invasive infusion, the
Singapore Stocks Open on Monday in Red; IX Biopharma's Stock Plunge 9% Following Contract Termination
Singapore Strait Times Index stayed in the red zone on Friday, despite overnight gains in global markets. During the day, the benchmark index ranged between 3,119.70 and 3,147.400, ending 0.43% or 13.
IX Biopharma's Subsidiary Issues Termination Notice for Licensing Agreement; Shares Plunge 9%
IX Biopharma's (SGX:42C) subsidiary, iX Biopharma Europe, issued a notice of termination of a license agreement with Seelos Therapeutics for the licensing of Wafermine, according to a filing on Friday
IX Biopharma Stays in Red in Fiscal H1
IX Biopharma (SGX:42C) reported a loss of SG$7.3 million in the fiscal fist half ended Dec. 31, 2023, largely unchanged from the loss it incurred a year earlier. Earnings per share attributable to equ
IX Biopharma Unit Ends Wafermine Licensing Deal With Seelos Therapeutics; Shares Tumble 10%
IX Biopharma (SGX:42C) subsidiary, iX Biopharma Europe, ended a licensing deal with Seelos Therapeutics that covered Wafermine, a pain and depression drug, a Friday filing showed. The terminated agree
IX Biopharma Unit Launches Anti Ageing Products in US
IX Biopharma (SGX:42C) unit Meltmed launched its suite of fast-dissolving wafer products, including feature nicotinamide adenine dinucleotide and glutathione, in the US. The Meltmed products are used
Singapore Stocks Snap Losing Streak; Oxley Shares Slip 4% on Expected Losses in Fiscal H2, Fiscal 2023
Singapore's Straits Times Index snapped its losing streak to return to positive territory on Tuesday, tracking overnight gains in Europe and a mixed close in the US. During the day, the benchmark inde
IX Biopharma Trims Losses in Fiscal H2; Shares Jump 17%
IX Biopharma's (SGX:42C) loss in the fiscal second half narrowed to SG$2.3 million, from the SG$8.3 million it booked a year earlier. Loss per share attributable to equity holders came in at SG$0.003,
IX Biopharma Gets Regulatory Nod to List Over 24 Million Shares; Shares Drop 5%
IX Biopharma (SGX:42C) obtained the listing and quotation notice from the Singapore Exchange for the listing and quotation of up to 24,420,024 conversion shares. The shares will be issued to Hong Kong
IX Biopharma to Issue SG$2 Million Worth of Convertible Bonds
IX Biopharma (SGX:42C) will issue SG$2 million worth of convertible bonds, convertible into new ordinary shares of the company, to Hong Kong-based private investor Lau Ho Ming Peter. The bonds carry a
IX Biopharma (Catalist:42C) Investors Are Sitting on a Loss of 64% If They Invested Three Years Ago
IX Biopharma First Half 2023 Earnings: S$0.01 Loss per Share (Vs S$0.005 Profit in 1H 2022)
IX Biopharma Turns to Loss in July-December 2022 as Revenue Plummets 81%
06:36 AM EST, 02/10/2023 (MT Newswires) -- IX Biopharma (SGX:42C) turned to a loss in the fiscal first half ended Dec. 31, 2022, as its revenue plummeted 81% as no payments were received from the out-
IX Biopharma Concludes Phase 1 Study on Dementia Treatment Drug
05:30 AM EST, 02/10/2023 (MT Newswires) -- IX Biopharma (SGX:42C) said it has "successfully completed" the phase 1 pharmacokinetic clinical study on the sublingual dexmedetomidine wafer, which is bei
IX Biopharma (Catalist:42C) Investors Are Sitting on a Loss of 44% If They Invested Three Years Ago
When Will IX Biopharma Ltd. (Catalist:42C) Turn A Profit?
Analysis
Price Target
No Data
